Approval · Notice of Compliance 13013 · 2012
RELISTOR: Notice of Compliance 13013
Issued February 3, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13013
- Date
- February 3, 2012
- Company
- Salix Pharmaceuticals IncBridgewater, New Jersey, United States
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- mcg-Opioid Receptor Antagonist
Products in this notice
Medicinal ingredients
- METHYLNALTREXONE BROMIDE 20 MG per ML